Skip to main content
Advanced Enzyme Technologies Limited logo

Advanced Enzyme Technologies Limited — Investor Relations & Filings

Ticker · ADVENZYMES ISIN · INE837H01020 LEI · 335800PWJRERMBTUUV90 BSE.NS Manufacturing
Open in API
Filings indexed 938 across all filing types
Latest filing 2025-09-19 Regulatory Filings
Country IN India
Listing BSE.NS ADVENZYMES

About Advanced Enzyme Technologies Limited

https://www.advancedenzymes.com/

Advanced Enzyme Technologies Limited is a research-driven company specializing in the development, manufacturing, and marketing of proprietary enzyme products and probiotics. The company operates across the entire enzyme value chain, from research and development to commercial-scale production. Its diverse portfolio serves multiple sectors, including human nutrition, animal nutrition, and industrial processing. Key applications encompass food and beverage production, dietary supplements, animal feed additives, and various industrial processes such as textiles, detergents, and pulp and paper manufacturing. With a focus on biotechnology and sustainable solutions, the firm leverages its extensive R&D capabilities to provide customized enzyme formulations. The company maintains a global footprint, supplying specialized biological solutions to a broad international client base.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about a scheduled analyst/institutional investor meeting. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides details of the meeting date, type, and participants. There is no financial data, no report attached or published, and no detailed presentation included. This is an announcement of an upcoming investor meeting rather than the meeting materials or transcript itself. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2025-09-19 English
Copy of Newspaper Publication
Regulatory Filings
2025-09-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of a conference call held on August 6, 2025, discussing the un-audited financial results for the quarter ended June 30, 2025. It includes management commentary, financial performance data, segment-wise revenue analysis, subsidiary performance, and a Q&A session with analysts and investors. The presence of forward-looking statements, detailed financial figures, and management discussion confirms this is a full transcript of an earnings call rather than a brief earnings release or a simple announcement. The document length (15,000 characters) and content depth further support this classification. Therefore, the document fits the definition of a Call Transcript (CT).
2025-08-11 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is an intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, regarding the availability of the audio recording of a conference call for the unaudited financial results for the quarter ended June 30, 2025. It mentions that the transcript will be provided later. The document is short (1699 characters) and serves as a notification about the conference call recording, not the transcript or the financial results themselves. Therefore, it is an announcement related to a conference call, not the full transcript. Given the nature of the document, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and notification rather than a full Call Transcript (CT) or Interim Report (IR).
2025-08-06 English
Copy of Newspaper Publication
Regulatory Filings Classification · 95% confidence The document is dated August 4, 2025, and is addressed to stock exchanges in India (BSE Limited and National Stock Exchange of India). It references the publication of an extract of un-audited consolidated financial results for the quarter ended June 30, 2025. The text mentions the newspaper publication of the extract of financial results, which is a summary or announcement rather than the full financial report itself. The document is about the announcement of the extract of quarterly financial results, not the full interim or quarterly report containing detailed financial statements and analysis. Therefore, this document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement of financial results publication, not the full Interim/Quarterly Report (IR).
2025-08-04 English
Acquisition
Interim / Quarterly Report Classification · 98% confidence The document is dated August 2, 2025, and is an official communication from Advanced Enzyme Technologies Limited to stock exchanges regarding the outcome of a Board Meeting held on the same date. The key content includes approval of unaudited financial results for the quarter ended June 30, 2025, along with a limited review report by the statutory auditors. The document contains detailed financial data for the quarter, including revenue, expenses, profit, and earnings per share, as well as notes explaining the scope and basis of the financial results. The presence of unaudited quarterly financial results, a limited review report, and detailed financial statements for a quarter strongly indicates this is an Interim / Quarterly Report. The document is substantive and contains actual financial data and analysis, not merely an announcement or certification. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2025-08-02 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.